Skip to main content

Losses and Lack of Cash at Sequenom Causes Its Accounting Firm to Identify Going Concern in 2005 Results

NEW YORK, April 7 (GenomeWeb News) - Sequenom's accounting firm has issued a "going concern qualification" on the company's financial statements for the year 2005, the company said yesterday.


Ernst & Young, Sequenom's independent registered public accounting firm, issued the concern on the 2005 results, filed on March 31, because of the company's significant operating losses and insufficient cash and investments to fund operations past the second quarter of 2006.


Last week, the company announced a private stock placement of $30 million, which it increased to $33 million on Monday.


As of Dec. 31, 2005, the company had $8.7 million in cash, cash equivalents, short-term investments and restricted cash. Net losses for 2005 declined to $26 million from $34 million year over year.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.